6 results
This study will evaluate the safety, efficacy, and pharmacokinetics of UTTR1147A compared with placebo and compared with vedolizumab in patients with moderate to severe ulcerative colitis (UC).
To determine the influence of darolutamide on the pharmacokinetics of cabazitaxel compared to cabazitaxel alone in mCRPC patients.
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.
To compare progression free survival (PFS) between treatment with docetaxel or cabazitaxel and darolutamide versus treatment with docetaxel or cabazitaxel in mCRPC patients.
Primary objectives:# To evaluate the safety of the combination of JNJ-63723283 with apalutamide.# To define a population of subjects with metastatic CRPC who respond to treatment with the combination of JNJ-63723283 and apalutamide.Secondary…